Disappointment & Surprise But Not Giving Up: Companies Respond To English Funding Rejection For COVID-19 Treatments

 
• By Neena Brizmohun

MSD, Gilead, GSK, AstraZeneca and Roche told the Pink Sheet what they thought of draft guidance that the health technology assessment institute, NICE, published today, recommending against routine commissioning for five COVID-19 treatments.

Balance scales with capsules pills and money coins. 3d render.
NICE is weighing up the cost-effectiveness of COVID-19 treatments • Source: Alamy

More from Market Access

More from Pink Sheet